Avian influenza virus prevention in the domestic host by a deactivated vaccine
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Abstract Influenza viruses, which affect both birds and mammals, pose a substantial public health concern. An estimated 10% of the global population annually becomes infected, resulting in 300,000 to 600,000 deaths worldwide. Our research objectives are to develop a Hemagglutinin (HA) and Neuraminidase (NA) based rabies-vectored vaccine against highly pathogenic Avian Influenza (HPAI) A virus H5N1. We have already demonstrated the vaccine’s immunogenicity and protective efficacy against HPAI H5N1 Vietnam 1203. To advance this research, we propose to utilize a novel RAVB-based deactivated vaccine that harbors the H5 antigens of the current homologous circulation (clade 2.3.4.4b) and a construct expressing N1. Our first aim will involve comparing the H5 or H5/N1 RABV-based vaccines against challenges by PR8 recombinants carrying H5N1 proteins in mice. We will employ a single immunization and a prime/boost approach, either with or without an adjuvant approved for use in animals and humans (SEPIVAC SWE™). We will assess the role of T cells in the vaccine-induced protection by performing CD4/CD8 depletion before challenge Our second aim will utilize the vaccine approach identified to protect our mouse system in dairy cows. Subsequently, we will assess the vaccine’s efficacy against challenges administered intranasally and intramammary. We will verify the role of the vaccine-induced antibodies in protection against H5N1 by performing passive transfer studies of purified IgG from vaccinated cows before challenge. In summary, this study will evaluate the efficacy and delineate the mechanism of protection of a safe and well- established vaccine platform to protect against HPAI H5 and explore its potential as an animal and human vaccine.
Grant Summary
Avian influenza virus prevention in the domestic host by a deactivated vaccine is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $221K for university, nonprofit, healthcare org. Applications are due 2028-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $221K
2028-05-31
- 1Confirm your organization is eligible for Avian influenza virus prevention in the domestic host by a deactivated vaccine from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Avian influenza virus prevention in the domestic host by a deactivated vaccine: Frequently Asked Questions
Who is eligible for the Avian influenza virus prevention in the domestic host by a deactivated vaccine?
Avian influenza virus prevention in the domestic host by a deactivated vaccine is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Avian influenza virus prevention in the domestic host by a deactivated vaccine provide?
Avian influenza virus prevention in the domestic host by a deactivated vaccine provides up to $221K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Avian influenza virus prevention in the domestic host by a deactivated vaccine deadline?
Applications for Avian influenza virus prevention in the domestic host by a deactivated vaccine are due 2028-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Avian influenza virus prevention in the domestic host by a deactivated vaccine?
To apply for Avian influenza virus prevention in the domestic host by a deactivated vaccine, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.